drugset / Trial / NCT01883297
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating lymphocytes (TILs), autologous dendritic cells (DCs), and OKT3 (anti-CD3 antibody), along with low-dose interleukin-2 (IL-2) therapy.
Timeline
- Start
- 2015-01
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Re-stimulated tumor-infiltrating lymphocytes (TILs) | Cell therapy | 3e+07 cells | Intravenous |
| Subject | Re-stimulated tumor-infiltrating lymphocytes (TILs) | Cell therapy | 1e+08 cells | Intravenous |
| Subject | Re-stimulated tumor-infiltrating lymphocytes (TILs) | Cell therapy | 3e+08 cells | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 30 mg/kg | Intravenous |